Recruiting
Phase 1

MB-CART19.1

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07137494

Conditions

Primary Central Nervous System (CNS) Lymphoma

Secondary Central Nervous System Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MB-CART19.1 Cellular Therapy

Study Details

Brief summary:

This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.

Conditions

Primary Central Nervous System (CNS) Lymphoma

Secondary Central Nervous System Lymphoma

Study ID

NCT07137494

Start date

Aug 14, 2025

Status verified date

Jun, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Aug, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men and women who are at least 18 years of age on the day of consenting to the study.
  • Histologically documented primary or secondary central nervous system lymphoma of DLBCL subtype
  • Relapsed/refractory primary or secondary CNSL patients. All relapsed//refractory patients need to have received at least one prior CNS-directed methotrexate-based therapy. There is no restriction on the number of recurrences.
  • For relapsed patients, parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) within 21 days of study consent.
  • For refractory patients, there must be residual disease after their last line of therapy.
  • For patients with leptomeningeal disease only, CSF cytology and/or flow cytometry must document CSF findings consistent with CSF involvement by lymphoma and/or imaging findings consistent with CSF disease within 21 days of study registration (at the discretion of the investigator).
  • Creatinine Clearance ≥ 40 ml/min/m2, direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN)
  • Adequate pulmonary function as assessed by ≥90% oxygen saturation on room air by pulse oximetry.
  • Must be able to tolerate both MRI and CT scans
  • Must be able to tolerate lumbar puncture and/or Ommaya taps
  • Must have been either off corticosteroids, or on a stable or decreasing dose of dexamethasone equivalent ≤ 2 mg daily for 7 days before apheresis and 72 hours prior to CAR T cell infusion o Use of corticosteroids to treat CAR T cell toxicities per MSKCC guidelines is permitted

Exclusion Criteria:

  • ECOG performance status >2

o Patients with ECOG status of 2 will be enrolled at the discretion of the PI
  • Active systemic lymphoma (i.e. involvement outside of the CNS)
  • If the most recent CSF or brain tissue sample demonstrates absence of CD19 expression
  • Size of any single CNS lymphoma lesion exceeds 3 cm in maximal diameter in eloquent brain structures.
  • Prior treatment of systemic lymphoma with CD19-targeted CAR T cells
  • Pregnant or lactating patients. Patients of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.
  • Impaired cardiac function (LVEF <40%) as assessed by most recent ECHO in the last 1 year.
  • Patients with autoimmune disease requiring systemic T cell-suppressive therapy.
  • Patients with following cardiac conditions will be excluded:

  • New York Heart Association (NYHA) stage III or IV congestive heart failure
  • Myocardial infarction ≤6 months prior to enrollment
  • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
  • Patients with ocular lymphoma in the absence of other CNS involvement
  • Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C, or 3 months since allogeneic hematopoietic stem cell transplantation, prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
  • Patients with HIV
  • Patients with active hepatitis B or hepatitis C infection (as manifested by either detectable hepatitis B virus DNA by PCR, hepatitis virus C RNA by PCR, or positivity for hepatitis B surface or core antigen)
  • Patients with uncontrolled systemic fungal, bacterial, viral or other infection at time of leukapheresis or at time of CAR T cell infusion
  • Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin
  • Patients exposed to immune checkpoint inhibitor within 8 weeks
  • Use of herbal supplements are not allowed on study
  • Any other issue which, in the opinion of the treating physician or PI, would make the patient ineligible for the study.

Study Design

Enrollment

12 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MB-CART19.1 Cellular Therapy

Following enrollment, patients will undergo leukapheresis of peripheral blood for mononuclear cell collection, followed by further T cell enrichment, activation and genetic modification using a lentiviral vector encoding a CD19 targeted CAR. These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operating procedures. Modified T cell infusions will be administered 2-7 days following completion of the conditioning chemotherapy. Serial sampling of blood and cerebrospinal fluid (CSF) will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.

Interventions

MB-CART19.1 Cellular Therapy

MB-CART19.1 will be infused as a single infusion during an inpatient admission.

Primary outcome measure

  • To identify the maximum tolerated dose (MTD) [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Ivan Kotchetkov, MD

212-610-0751kotcheti@mskcc.org

Maria Palomba, MD

646-608-3711

Locations

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Ivan Kotchetkov, MD

212-610-0751

Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Ivan Kotchetkov, MD

212-610-0751

Memorial Sloan Kettering at Bergen (Limited Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Ivan Kotchetkov, MD

212-610-0751

Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Ivan Kotchetkov, MD

212-610-0751

Memorial Sloan Kettering at Westchester (Limited Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Ivan Kotchetkov, MD

212-610-0751

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Ivan Kotchetkov, MD

212-610-0751kotcheti@mskcc.org

Maria Palomba, MD

646-608-3711

Memorial Sloan Kettering at Nassau (Limited Protocol Activities)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Ivan Kotchetkov, MD

212-610-0751

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Jun 5, 2026

Last verified

Jun, 2026

Keywords

  • MB-CART19.1 Cellular Therapy
  • Relapsed/Refractory
  • CliniMACS Prodigy Device

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-06-05.